肺腺癌是近年来发病率和死亡率不断上升的肿瘤之一。现有的血清标志物浓度的异常并不能同步反映肺腺癌的发生发展，对其早期预警作用更差。寻找新型有效的肺腺癌预警监测和早期诊断的生物标志物需另辟新径。人类微生物组研究已成为肿瘤精准医学研究的重要领域之一。本项目以 “人体微生物基因组与人自身基因相互作用，共同决定人体免疫监视功能状态”为切入点，采用宏基因组学、免疫组学及大数据生物信息分析手段，解析肺腺癌患者口腔、肺及肠道微生物宏基因组和血清细胞因子变化特征，并与疾病进展关联分析，阐明人体微生态失衡参与肺腺癌发生发展的整合组学机制，确定与肺腺癌发生发展相关的生物标记物，建立基于人体微生物组大数据的肺腺癌早期预警监测模型。预期成果对肺腺癌病因、发病机制、防治具有重要意义。项目以国家重点实验室为支撑，聘请微生态学专家，成员曾在Nature、hepatology发表论文，工作基础扎实，可保证项目的顺利进行。

Lung Adenocarcinoma (LA) is one of cancers, which have been increasing in incidence and mortality in recent years. The abnormal concentration of the existing serum markers does not synchronously reflect the occurrence and development of LA, and is worse for early warning effect. Therefore, we need to develop a method to identify new and effective biomarkers for early warning monitoring and diagnosis of lung Adenocarcinoma. Currently, the study of the human microbiome has become one of the important fields in the research of tumor precision medicine. This study is according to “human microbiome determines the state of human immune surveillance in cooperation with host genes”. We apply multiple technologies, which include metagenomics, immunomics and bioinformatics to reveal the dynamic characteristics of oral, lung and gut microbiome and serum cytokines in health people and patients with LA. We will associate these alterations with disease progression to clarify the integrative metagenomics and immunomics mechanism, via which the oral, lung and gut microbial imbalances are involved in LA progression, and identify the key biomarkers for the early warning and monitoring model of LA based on large data of human microbiome. The expected results of this project are significant to etiology, pathogenesis, diagnosis and then treatment of LA. This study will be supported by the State Key Laboratory, supervised by a world-class microbial ecologist, and conducted by members who have published in Nature and Hepatology.